All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
NICE draft guidance is currently minded to not recommend OPDIVO® (nivolumab) for relapsed/refractory classical Hodgkin Lymphoma – unless updated analyses are provided
Earlier this month, the National Institute for Health and Care Excellence (NICE) published draft guidance on OPDIVO® (nivolumab) for the treatment of Relapsed/Refractory (R/R) classical Hodgkin Lymphoma (cHL).
The initial evidence presented by Bristol-Myers Squibb (BMS) was immature data and did not reflect how nivolumab would be used in UK clinical practice, causing uncertainty. Thus, NICE is of the opinion to not recommend nivolumab as an option for R/R cHL after ASCT and treatment with brentuximab vedotin; unless BMS can deliver revised data.
NICE stressed that the updated analyses should include cost-effectiveness data and comparisons to the current standard of care used in the UK, using UK data.
OPDIVO® was awarded a CHMP positive opinion and approval by the European Medicines Agency (EMA) for the treatment of R/R cHL after ASCT and treatment with brentuximab vedotin in November 2016.
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?